The ExoCordOA consortium has announced the launch of a five-year, €13 million project, funded by Horizon Europe to advance extracellular vesicle-enriched secretome therapies towards clinical use, with an initial focus on osteoarthritis. Led by Exogenus Therapeutics, ExoCordOA brings together ten organisations with complementary expertise across biotechnology, clinical and regulatory development, GMP manufacturing, medical imaging, academia […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
